DeZure Adam D, Berkowitz Nina M, Graham Barney S, Ledgerwood Julie E
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
J Infect Dis. 2016 Dec 15;214(suppl 5):S497-S499. doi: 10.1093/infdis/jiw352.
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics.
基孔肯雅病毒（CHIKV）是一种全球公共卫生威胁，已在亚洲、非洲、欧洲和美洲的60多个国家被发现。目前尚无针对CHIKV感染的治愈方法或获批疫苗。CHIKV疫苗研发的最初尝试始于20世纪60年代初。全灭活疫苗和病毒样颗粒（VLP）疫苗是目前正在评估的两种方法。这些方法的成功取决于一种安全、耐受性良好、具有免疫原性且在生产、稳定性和递送特性方面可部署的疫苗。
